ArticleMolecular biology reports2026
Increased Carbapenem resistance and gene carriage in Pseudomonas aeruginosa clinical isolates after the COVID-19 pandemic in Egypt.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe coronavirus disease 2019 (COVID-19) pandemic has significantly influenced antimicrobial resistance dynamics, leading to a rise in multidrug resistance (MDR) rates in several bacterial species. Carbapenem-resistant Pseudomonas aeruginosa (CRPA) has emerged as a significant global public health concern due to the scarcity of effective treatment options. This study aimed to assess the frequency and molecular determinants of carbapenem resistance in clinical CRPA isolates before and after the COVID pandemic.
methodsA total of 67 clinical isolates of CRPA were identified from 300 P. aeruginosa isolates collected from patients with various infections. Phenotypic characterization of CRPA isolates was performed using the broth microdilution method. Conventional PCR analysis was employed to detect the presence of integrons and 14 carbapenemase-encoding genes among CRPA isolates.
resultsOut of 300 P. aeruginosa isolates, 67 were identified as CRPA. Among these, 36 out of 200 isolates (18%) were obtained before the COVID-19 pandemic and 31/100 (31%) were collected after the pandemic. In this study, post-COVID CRPA isolates showed significantly higher carbapenem MICs (≥ 128 µg/mL; 90.3%) compared to pre-COVID isolates (16.7%) (P = 0.0001). MDR was identified in 43 of 67 (64.2%) CRPA isolates, more frequently post-COVID (71% vs. 58.3%) (P = 0.2). The bla
conclusionOur findings reveal a high prevalence of carbapenemase-encoding genes and class 1 integrons in post-COVID CRPA clinical isolates, highlighting the evolving nature of antimicrobial resistance and the critical role of integrons in gene transfer. The emergence of strains co-producing multiple enzymes is particularly alarming. Further molecular understanding of resistance mechanisms of CRPA strains is essential for effective clinical management and the development of robust infection control measures.
Indexed as
Identifiers
42234289What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.